Arca Biopharma | ABIO - Ebitda


Arca Biopharma reported $-25.07M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 5.14B 775M Dec/2025
Arca Biopharma USD -25.07M 5.23M Mar/2025
Biogen USD 649.7M 76.5M Mar/2026
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Cytokinetics USD -149.83M 127.34M Dec/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Grifols EUR 482.04M 7.04M Sep/2025
Laboratory Of America USD 605.6M 17.5M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Otsuka Holdings JPY 156.66B 56.89B Mar/2026
Pfizer USD 756M 5.32B Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025